Biotech Archives - Page 68 of 795

2 minute read

J&J Braces For Q1 Earnings With Bearish Charts And Patent Cliffs In Play

April 15, 4:47 PM

Johnson & Johnson's Q1 earnings report on April 16 is expected to show $2.64 EPS and $21.4 billion in revenues. Technical analysis shows a bearish trend but analysts have a neutral rating with a $171.95 price target and potential 37.15% upside.

JNJ

4 minute read

Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends

By Lara Goldstein

April 15, 4:13 PM

Psychedelics healthcare company Numinus Wellness (OTCQX:NUMIF) shared its unaudited, condensed and consolidated interim financial results for the three…

NUMIF

2 minute read

Prothena Announces Review On Birtamimab Mechanism Of Action And Pharmacological Characteristics Published In Leukemia & Lymphoma

By Benzinga Newsdesk

April 15, 4:10 PM

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the publication related

PRTA

4 minute read

Novartis Fabhalta Data Show Clinically Meaningful And Statistically Significant Proteinuria Reduction Of 38.3% Versus Placebo For Patients With IgA Nephropathy

By Benzinga Newsdesk

April 15, 2:01 PM

APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1 IgAN is a heterogeneous, progressive, rare kidney disease

NVS

1 minute read

Why Is Penny Stock Soligenix Trading Higher On Monday?

By Vandana Singh

April 15, 1:55 PM

Soligenix secures FDA orphan drug designation for MarVax, a vaccine against Marburg marburgvirus (MARV). Benefits include market exclusivity, financial perks, and potential FDA fee waivers. MARV, akin to Ebola, lacks approved vaccines, highlighting urgent need."

SNGX

1 minute read

Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?

By Vandana Singh

April 15, 12:16 PM

Nanatinostat combined with valganciclovir shows promising results in treating relapsed or refractory EBV+ peripheral T-cell lymphoma, demonstrating higher efficacy and tolerability than nanatinostat monotherapy.

VIRX

2 minute read

Abbott/Thoratec Corp. Recalls HeartMate II And HeartMate 3 Left Ventricular Assist System Due To Long-term Buildup Causing An Obstruction

By Benzinga Newsdesk

April 15, 11:26 AM

Please be aware, this recall is a correction, not a product removal.The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or

ABT

2 minute read

Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study

By Vandana Singh

April 15, 10:40 AM

New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding natural history data.

RARE

2 minute read

Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?

By Vandana Singh

April 15, 10:17 AM

Neumora Therapeutics faces setbacks as FDA halts Phase 1 trial of NMRA-266 due to convulsion concerns in rabbits. Phase 1 study paused; company working with FDA for resolution.

NMRA

2 minute read

Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?

By Vandana Singh

April 15, 10:13 AM

Marinus Pharmaceuticals provides updates on Phase 3 RAISE trial for refractory status epilepticus treatment with IV ganaxolone. With enrollment completion expected, topline results are anticipated by summer 2024.

MRNS